Author

Kamlesh Kumar Bisht

Observed names: Bisht, Kamlesh, K K Bisht, K. Bisht, K. K. Bisht, Kamlesh Bisht, Kamlesh K Bisht, Kamlesh K. Bisht

Observed institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, University of Michigan, Peking Union Medical College Hospital, Sanofi (France), Moffitt Cancer Center, Bristol-Myers Squibb (United States), Sanofi (United States), Hospital Clínic de Barcelona, Institut de génétique et de développement de Rennes, Institute of Microbial Technology, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Celgene (United States), New York University, Council of Scientific and Industrial Research, Istanbul University, Erciyes University

ORCID: 0009-0003-3808-924X

Observed ORCID: 0009-0003-3808-924X

OpenAlex ID: A5082118917

EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda

2010 · Shilpi Aggarwal, Sapna Negi, et al. · Proceedings of the National Academy of Sciences · 175

Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1

2014 · Hande Kocak, Bari J. Ballew, et al. · Genes & Development · 129

PDF

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

2020 · Erin Flynt, Kamlesh Bisht, et al. · Cells · 78

PDF

Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis

2016 · P Gu, Y Wang, et al. · Oncogene · 60

The shelterin complex and hematopoiesis

2016 · Morgan Jones, Kamlesh Bisht, et al. · Journal of Clinical Investigation · 60

PDF

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

2020 · Mike J. Mason, Carolina Schinke, et al. · Leukemia · 52

PDF

GDP-Mannose-4,6-Dehydratase Is a Cytosolic Partner of Tankyrase 1 That Inhibits Its Poly(ADP-Ribose) Polymerase Activity

2012 · Kamlesh K. Bisht, Charles Dudognon, et al. · Molecular and Cellular Biology · 52

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

2023 · Kamlesh Bisht, Taro Fukao, et al. · Cancer Medicine · 48

PDF

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

2022 · Tom Martin, Paul G Richardson, et al. · Haematologica · 44

PDF

SA1 binds directly to DNA via its unique AT-hook to promote sister chromatid cohesion at telomeres

2013 · Kamlesh K. Bisht, Zharko Daniloski, et al. · Journal of Cell Science · 44

Structural and functional consequences of a disease mutation in the telomere protein TPP1

2016 · Kamlesh Bisht, Eric M. Smith, et al. · Proceedings of the National Academy of Sciences · 41

PDF

Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies

2021 · Kamlesh Bisht, Brian Walker, et al. · Expert Review of Hematology · 40

RETRACTED: Leishmania donovani Isolates with Antimony-Resistant but Not -Sensitive Phenotype Inhibit Sodium Antimony Gluconate-Induced Dendritic Cell Activation

2010 · Arun Kumar Haldar, Vinod Yadav, et al. · PLoS Pathogens · 39

PDF

Consortium IGVThe Indian Genome Variation database (IGVdb): a project overview. Hum Genet 118:1-11

2005 · Samir K. Brahmachari, Lalji Singh, et al. · 37

Two Separation-of-Function Isoforms of Human TPP1 Dictate Telomerase Regulation in Somatic and Germ Cells

2019 · Sherilyn Grill, Kamlesh Bisht, et al. · Cell Reports · 28

PDF

Resolution of human ribosomal DNA occurs in anaphase, dependent on tankyrase 1, condensin II, and topoisomerase IIα

2019 · Zharko Daniloski, Kamlesh K. Bisht, et al. · Genes & Development · 25

PDF

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

2024 · Anna Luise Grab, Peter S. Kim, et al. · Cells · 23

Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

2024 · Alana L. Keller, Lauren T. Reiman, et al. · Cancer Research Communications · 19

PDF

Role of heterochromatin in suppressing subtelomeric recombination in fission yeast

2008 · Kamlesh Kumar Bisht, Sumit Arora, et al. · Yeast · 14

Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities

2024 · Kamlesh Bisht, Aimee Merino, et al. · Experimental Hematology and Oncology · 13

Interaction of APC/C-E3 Ligase with Swi6/HP1 and Clr4/Suv39 in Heterochromatin Assembly in Fission Yeast

2009 · Rudra Narayan Dubey, Nandni Nakwal, et al. · Journal of Biological Chemistry · 12

PDF

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

2024 · Thierry Facon, Philippe Moreau, et al. · Hematological Oncology · 11

PDF

The Indian Genome Variation Consortium The Indian Genome Variation database (IGVdb): a project overview

2005 · Samir K. Brahmachari, Lalji Singh, et al. · 11

A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies

2024 · Aintzane Zabaleta, Laura Blanco, et al. · British Journal of Haematology · 10

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

2024 · Esperanza Martín-Sánchez, Laura Blanco, et al. · Blood Advances · 10

Works count: 102

Citation count: 1,140

H-index: 18

I10-index: 25